Linzagolix

Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids and endometriosis. Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) developed by Kissei Pharmaceutical and ObsEva. In June 2022, it was approved for medical use in the European Union and in the United Kingdom.
Wikipedia contributors, "Linzagolix", Wikipedia, revision 1328695350, retrieved 20 November 2026, source, CC BY-SA 4.0.